Abstract
This study addresses the social relevance of low-prevalence childhood diseases and reports the process of generation and validation of a tool to assess the social impact on the direct family environment and the social context of reference. The aim of the process of construction and validation of this instrument is to provide the field with a tool with the capacity to shed light on the social consequences of suffering from a low-prevalence disease, specifically those comorbid with treatment-resistant epileptic seizures of childhood origin. The instrument here presented and called CRESIA (acronym derived from Childhood Rare Epilepsy Social Impact Assessment) provides valuable information on six specific areas framing health, economic, psychological, social, and child-related stressors, as well as family. CRESIA represents a valid and reliable instrument for family members or primary caregivers of children and adolescents with childhood rare epilepsy.
Funder
Ayudas Fundación BBVA a Proyectos de Investigación Científica 2021
Reference47 articles.
1. Estimating cumulative point prevalence of rare diseases: Analysis of the Orphanet database;Eur. J. Hum. Genet.,2020
2. (2022, October 10). Orphanet, Procedural document on the Orphanet nomenclature and classification of rare diseases, Orphanet 2020, Number 2. Available online: https://www.orpha.net/orphacom/cahiers/docs/GB/eproc_disease_inventory_R1_Nom_Dis_EP_04.pdf.
3. Recommendations for the development of national plans for rare diseases;Orphanet J. Rare Dis.,2010
4. Why rare diseases are an important medical and social issue;Lancet,2008
5. Huml, R.A. (2021). Rare Disease Drug Development, Springer.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献